Company intelligence / Profile preview

ILGEN

Syracuse, New York, United States
Ownership
Private
Development stage
Preclinical
01

Overview

ILGEN has developed a proprietary platform to rapidly generate and select high-affinity, fully human monoclonal antibodies for therapeutic and diagnostic use. Their approach significantly reduces the time required to obtain validated antibody candidates compared to traditional methods. The company’s pipeline includes an anti-LAG3 antibody program and a human fusion protein (ILG-F), with applications in cancer, autoimmune, infectious, vascular, and lymphoproliferative diseases. No published clinical results are available as of now[1][3].

Therapeutic areas
CardiovascularRheumatologyImmunologyHematologyOncologyInfectious Diseases
Modalities
Fully human monoclonal antibodiesFusion proteins (e.g., human fusion protein ILG-F)
Industry
Biotech
02

Drug pipeline

2 assets

ILGEN anti-LAG-3 antibody

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on ILGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILGEN.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call